Loxapine: a six-month evaluation in severely ill schizophrenic patients.
D000284:Administration, Oral; D000328:Adult; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000188:drug therapy; D002908:Chronic Disease; D003989:Dibenzoxazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D013386:Succinates / Q000008:administration & dosage / Q000627:therapeutic use; D013610:Tachycardia / Q000139:chemically induced; D014149:Tranquilizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D003989:Dibenzoxazepines; D010879:Piperazines; D013386:Succinates; D014149:Tranquilizing Agents